Почетна › Многи мијелом › Тексас › Houston
Kliničke studije za Многи мијелом u gradu Houston, TX
39 studija za Многи мијелом traži učesnike na lokacijama u gradu Houston i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Тражи се учесникФаза 3
- Houston Methodist Cancer Center Infusion, Houston
- Houston Methodist Hospital - Department of Pharmacy, Houston
- Houston Methodist Hospital Cancer Center, Houston
- и још 3
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Тражи се учесникФаза 3
- MD Anderson Cancer Center, Houston
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Oncology Consultants /ID# 268323, Houston
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Тражи се учесникФаза 4
- MD Anderson Cancer Center, Houston
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Тражи се учесникФаза 3
- Houston Methodist Hospital, Houston
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 3
- MD Anderson Cancer Center, Houston
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Тражи се учесникОпсервациона студија
- MDA, Houston
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Тражи се учесникФаза 2Здраве особе су добродошле
- MD Anderson Cancer Center, Houston
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Тражи се учесникФаза 1
- Houston Methodist Hospital, Houston
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Тражи се учесникФаза 3
- University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Тражи се учесникФаза 3
- The University of Texas MD Anderson Cancer Center, Houston
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Oncology Consultants, Houston
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Тражи се учесникФаза 3
- Research Site, Houston
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
Тражи се учесникФаза 2
- M D Anderson Cancer Center, Houston
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1/2
- Research Site, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Тражи се учесникФаза 3
- The University of Texas MD Anderson Cancer Center, Houston
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Тражи се учесникФаза 1/2
- Research Site, Houston
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 2
- University of Texas MD Anderson Cancer Center, Houston
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Тражи се учесникФаза 3
- Research Site, Houston
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Тражи се учесникФаза 1
- Research Site, Houston
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1/2
- MD Anderson, Houston
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Тражи се учесникФаза 1
- Oncology Consultants (P1 Trials -Exigent Network), Houston
- Lumi Research, Houston
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Тражи се учесникФаза 2
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
Тражи се учесникФаза 2
- MD Anderson Cancer Center, Houston
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Тражи се учесникФаза 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Тражи се учесникФаза 3
- Research Site, Houston
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
Тражи се учесникФаза 1/2
- M D Anderson Cancer Center, Houston
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
Тражи се учесникФаза 2
- MD Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Тражи се учесникФаза 1/2
- M D Anderson Cancer Center, Houston
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- University of Texas MD Anderson Cancer Center, Houston
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Тражи се учесникФаза 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- M D Anderson Cancer Center, Houston
- и још 2
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Тражи се учесникОпсервациона студија
- M D Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
ATRA and Carfilzomib in Plasma Cell Myeloma Patients
Тражи се учесникФаза 1/2
- Houston Methodist Neal Cancer Center, Houston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Тражи се учесникФаза 1/2
- MDACC, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Тражи се учесникФаза 1/2
- University of Texas MD Anderson Cancer Center, Houston
Studije za Многи мијелом u drugim gradovima
- New York City, NY59 студија
- Boston, MA45 студија
- Atlanta, GA42 студија
- Durham, NC36 студија
- Nashville, TN31 студија
- Denver, CO26 студија
- St. Louis, MO26 студија
- Rochester, MN25 студија
- Columbus, OH25 студија
- Chicago, IL24 студија
- Milwaukee, WI23 студија
- Baldwin Park, CA23 студија
Ostale studije u gradu Houston
- Немалоклетни карцином плућа143 студија
- Рак дојке126 студија
- Рак (све врсте)124 студија
- Колоректални карцином101 студија
- Метастатски карцином100 студија
- Рак јајника90 студија
- Akutna mijeloidna leukemija88 студија
- Рак плућа78 студија
- Рак простате73 студија
- Карцином ендометријума69 студија
- Меланом61 студија
- Рак панкреаса59 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.